Opinion

Video

Understanding Differences in Fusion-Guided Biopsy Technologies

Author(s):

David I. Lee, MD, FACS,Firas F. Abdollah, MD

Experts on prostate cancer focus on the differences between fusion-guided technologies, highlighting cognitive-based and software-based fusions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following questions:

      • When considering fusion-guided technologies, what is the difference between cognitive-based fusion and software-based fusion? What about rigid fusion and elastic fusion?
      Related Videos
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
      Dr Louise Kostos answers a question during a Zoom video interview
      An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
      Rana McKay, MD, on the role of radium-223 in the modern era
      Rana McKay, MD, on the role of radium-223 in the modern era
      Dr Louise Kostos answers a question during a Zoom video interview
      Dr Louise Kostos discusses PSA kinetics in mHSPC
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Laura Bukavina, MD, on trial of radiation with concurrent sacituzumab govitecan in MIBC
      Related Content
      Urologists perform first remote robot-assisted HIFU for prostate cancer
      April 17th 2025

      Urologists perform first remote robot-assisted HIFU for prostate cancer

      Hannah Clarke
      “We are witnessing the dawn of teletreatment,” says Jihad Kaouk, MD, FACS.
      Dr. Murphy on increasing diversity in cancer clinical trials
      February 29th 2024

      Dr. Murphy on increasing diversity in cancer clinical trials

      Urology Times staff
      In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
      Study underway to assess 3-fraction SBRT regimen in prostate cancer
      April 14th 2025

      Study underway to assess 3-fraction SBRT regimen in prostate cancer

      Hannah Clarke
      "The goal of the PRECISION study is to ensure that treatment with 3 radiation doses does not lead to greater side effects than those observed in the PACE-B study," says Professor Duncan B. McLaren, MBBS.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Label change for testosterone: Implications for urologists, prescribers, and patients
      April 9th 2025

      Label change for testosterone: Implications for urologists, prescribers, and patients

      Hannah Clarke
      In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
      Genetic test can predict risk of toxicity following radiation for prostate cancer
      April 7th 2025

      Genetic test can predict risk of toxicity following radiation for prostate cancer

      Hannah Clarke
      "This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
      © 2025 MJH Life Sciences

      All rights reserved.